Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus
NCT01235819 on ClinicalTrials.gov · last registry update 2016-07-27
A small phase 4 — 20 participants, against a typical 75. The sponsor logged completion for September 2011. Primary outcome, as filed: change in insulin requirement. exenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Command Hospital, India
- Sponsor type
- Other Gov
- Enrollment
- 20
- Started
- 2010-11
- Primary completion
- 2011-09 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
change in insulin requirement
Conditions studied
Type 1 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.